# NRC Health: overview

NRC · Nasdaq · CIK 70487 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nrc.md) · [Financials](/companies/nrc/financials.md) · [Filings](/companies/nrc/filings.md) · [Insiders](/companies/nrc/insiders.md)

Latest reported revenue: [$35.4m](/filings/0001437749-26-025624.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-025624).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [35.8](/filings/0001437749-25-033793.md) | [36.9 d](/filings/0001437749-26-007002.md) | [33.6](/filings/0001437749-26-015083.md) | [34.0](/filings/0001437749-26-025624.md) | [34.6](/filings/0001437749-25-033793.md) | [35.2 d](/filings/0001437749-26-007002.md) | [34.8](/filings/0001437749-26-015083.md) | [35.4](/filings/0001437749-26-025624.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [22.3%](/filings/0001437749-25-033793.md) | [26.0% d](/filings/0001437749-26-007002.md) | [25.6%](/filings/0001437749-26-015083.md) | [4.7%](/filings/0001437749-26-025624.md) | [22.4%](/filings/0001437749-25-033793.md) | [13.3% d](/filings/0001437749-26-007002.md) | [16.0%](/filings/0001437749-26-015083.md) | [(9.1%)](/filings/0001437749-26-025624.md) |
| Net margin | % | [15.9%](/filings/0001437749-25-033793.md) | [17.8% d](/filings/0001437749-26-007002.md) | [17.2%](/filings/0001437749-26-025624.md) | [(0.3%)](/filings/0001437749-26-025624.md) | [11.9%](/filings/0001437749-25-033793.md) | [5.1% d](/filings/0001437749-26-007002.md) | [9.3%](/filings/0001437749-26-025624.md) | [(9.3%)](/filings/0001437749-26-025624.md) |
| Diluted EPS | $ per share | [0.24](/filings/0001437749-25-033793.md) | not reported | [0.25](/filings/0001437749-26-015083.md) | [(0.01)](/filings/0001437749-26-025624.md) | [0.18](/filings/0001437749-25-033793.md) | not reported | [0.14](/filings/0001437749-26-015083.md) | [(0.15)](/filings/0001437749-26-025624.md) |
| Free cash flow | $m | [7.8 d](/filings/0001437749-25-033793.md) | [1.9 d](/filings/0001437749-26-007002.md) | [3.7](/filings/0001437749-26-015083.md) | [(4.1) d](/filings/0001437749-26-025624.md) | [10.2 d](/filings/0001437749-25-033793.md) | [6.1 d](/filings/0001437749-26-007002.md) | [5.3](/filings/0001437749-26-015083.md) | [0.1 d](/filings/0001437749-26-025624.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [148](/filings/0001437749-24-005690.md) | [152](/filings/0001437749-25-007867.md) | [149](/filings/0001437749-26-007002.md) | [143](/filings/0001437749-26-007002.md) | [137](/filings/0001437749-26-007002.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [34.0%](/filings/0001437749-24-005690.md) | [30.7%](/filings/0001437749-25-007867.md) | [27.0%](/filings/0001437749-26-007002.md) | [24.6%](/filings/0001437749-26-007002.md) | [16.4%](/filings/0001437749-26-007002.md) |
| Net margin | % | [25.3%](/filings/0001437749-24-005690.md) | [21.0%](/filings/0001437749-25-007867.md) | [20.8%](/filings/0001437749-26-007002.md) | [17.3%](/filings/0001437749-26-007002.md) | [8.4%](/filings/0001437749-26-007002.md) |
| Diluted EPS | $ per share | [1.46](/filings/0001437749-24-005690.md) | [1.27](/filings/0001437749-25-007867.md) | [1.25](/filings/0001437749-26-007002.md) | [1.04](/filings/0001437749-26-007002.md) | [50.00](/filings/0001437749-26-007002.md) |
| Free cash flow | $m | [40.8](/filings/0001437749-24-005690.md) | [26.4](/filings/0001437749-25-007867.md) | [22.3](/filings/0001437749-26-007002.md) | [19.2](/filings/0001437749-26-007002.md) | [15.7](/filings/0001437749-26-007002.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nrc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC](/funds/1021223.md) | 2026-06-30 | $43.8m | 2,030,492 |  | Reduced −605,863 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $22.9m | 1,061,355 |  | Added +85,500 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $18.5m | 859,269 |  | Reduced −142,611 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $14.4m | 666,554 |  | Added +3,717 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $10.6m | 491,228 |  | Added +1,488 |
| [Willis Investment Counsel](/funds/1310929.md) | 2026-06-30 | $9.4m | 434,785 |  | Added +210,147 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $9.1m | 420,056 |  | Added +26,209 |
| [FARMERS & MERCHANTS INVESTMENTS INC](/funds/1259969.md) | 2026-06-30 | $7.1m | 330,649 |  | Added +330,549 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $7.0m | 325,384 |  | Reduced −15,400 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $6.5m | 298,384 |  | Reduced −2,364 |

## Recent filings

[All 930 filings](/companies/nrc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 10:28 ET | [8-K](/filings/0001437749-26-032899.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-032899 |
| 2026-08-11 | 16:31 ET | [8-K](/filings/0001437749-26-027031.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-027031 |
| 2026-08-04 | 14:38 ET | [10-Q](/filings/0001437749-26-025624.md) | Quarterly report, period 2026-06-30 | 0001437749-26-025624 |
| 2026-07-28 | 16:03 ET | [8-K](/filings/0001437749-26-024663.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-024663 |
| 2026-06-29 | 13:04 ET | [8-K](/filings/0001437749-26-021938.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-021938 |
| 2026-06-12 | 16:24 ET | [SCHEDULE 13D/A](/filings/0001008886-26-000164.md) | Ownership report, active investor, amended | 0001008886-26-000164 |
| 2026-05-08 | 09:44 ET | [DEF 14A](/filings/0001437749-26-015775.md) | Proxy statement, period 2026-06-23 | 0001437749-26-015775 |
| 2026-05-06 | 11:42 ET | [10-Q](/filings/0001437749-26-015083.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015083 |
| 2026-04-28 | 17:16 ET | [10-K/A](/filings/0001437749-26-013686.md) | Annual report, amended, period 2025-12-31 | 0001437749-26-013686 |
| 2026-04-28 | 16:03 ET | [8-K](/filings/0001437749-26-013646.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-013646 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-007002.md), filed Mar 5, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d5964c7b-17e2-485a-b034-8a7367930ec5)

## About the filer

- CIK: 70487
- Tickers: NRC
- Exchange: Nasdaq
- SIC code: 8731 Services-Commercial Physical & Biological Research
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:03 ET. No prices; not investment advice.